Document:

Voting Agreement dated December 20, 2007

 Exhibit 10.8 
 CHINA NUOKANG BIO-PHARMACEUTICAL PTY 
 VOTING
AGREEMENT 
 This Voting Agreement (the “Agreement”) is made and entered into as of December 20,
2007 by and among CHINA NUOKANG BIO-PHARMACEUTICAL PTY (formerly Brighter Sky Limited), a Cayman Islands exempted company (the “Company”), Anglo China Bio-Technology Investment Holdings Limited and Britain Ukan Technology Investment
Holdings (Group) Limited, each a company organized and existing under the laws of the British Virgin Islands (collectively, the “Management Holding Companies”), the person set forth on Exhibit A hereto (the
“Management Shareholder”) and the holders of Preference A Shares listed on Exhibit A hereto (collectively, the “Preference A Holders” or “Investors”). 
 RECITALS 
 The Company, the Management Shareholder and the Investors have entered into a Preference A Shares Purchase Agreement dated as of the date hereof (the “Purchase Agreement”), pursuant to which the Company desires to sell to
the Investors and the Investors desire to purchase from the Company its Preference A Shares. A condition to the Investors’ obligations under the Purchase Agreement is that the Company, the Management Holding Companies, the Management
Shareholder and the Investors enter into this Agreement for the purpose of setting forth the terms and conditions pursuant to which the Investors and the Management Holding Companies shall, and the Management Shareholder shall cause the Management
Holding Companies, to (and to the extent the Management Shareholder receives shares of the Company in the future, such Management Shareholder himself shall), vote their shares of the Company in favor of certain designees to the Company’s Board
of Directors (the “Board of Directors”). The Company, the Management Holding Companies, the Management Shareholder and the Investors each desires to facilitate the voting arrangements set forth in this Agreement, and the sale and
purchase of Preference A Shares pursuant to the Purchase Agreement, by agreeing to the terms and conditions set forth below. 
 AGREEMENT 
 The parties agree as follows: 
 1. Election of Directors. Each Investor, as a holder of Preference A Shares, hereby agrees on behalf of itself and any
transferee or assignee of any such Preference A Shares, to hold all of the Preference A Shares registered in its name (and any securities of the Company issued with respect to, upon conversion of, or in exchange or substitution for such Preference A
Shares, and any other voting securities of the Company subsequently acquired by such Investor) and any voting securities of the Company held in trust over which they have voting power (hereinafter collectively referred to as the “Investor
Shares”) subject to, and to vote the Investor Shares at a regular or special meeting of shareholders (or by written consent) in accordance with, the provisions of this Agreement. Each Management Holding Company, as a holder of Ordinary
Shares and, if applicable, Preference A Shares of the Company, hereby agrees on behalf of itself and any transferee or assignee of any such Ordinary Shares and, if applicable, Preference A Shares, to hold all of such Ordinary Shares, Preference A
Shares and any other securities of the Company acquired by such Management Holding Company in the future (and any securities of the Company issued with respect to, upon conversion of, or in exchange or substitution for such securities) (the
“Management Holding Company Shares”) subject to, and to vote the Management Holding Company Shares at a regular or special meeting of shareholders (or by written consent) in accordance with, the provisions of this Agreement. The
Management Shareholder hereby agrees (a) on behalf of itself and any transferee or assignee of any securities in any Management Holding Company to cause such Management Holding Company to vote the Management Holding Company Shares at a regular
or special meeting of shareholders (or by written consent) in accordance with, the provisions of this Agreement and (b) if and when applicable, as a holder of Ordinary Shares and Preference A Shares of the Company, on behalf of itself and any
transferee or assignee of any such Ordinary Shares and Preference A Shares, to hold all of such Ordinary Shares, Preference A Shares and any other securities of the Company acquired by such Management Shareholder in the future (and any securities of
the Company issued with respect to, upon conversion of, or in exchange or substitution for such securities) (the “Management Shares”) subject to, and to vote the Management Shares at a regular or special meeting of shareholders (or
by written consent) in accordance with, the provisions of this Agreement. 
  

 1 

 1.1 Board Representation. At each annual meeting of the members of the
Company, or at any meeting of the members of the Company at which members of the Board of Directors are to be elected, or whenever members of the Board of Directors are to be elected by written consent, the Management Holding Companies, the
Management Shareholder and the Investors agree to vote or act with respect to their shares which they have control so as to elect: 
 (a) four (4) members of the Company’s Board of Directors designated by the Management Holding Companies (the “Ordinary Directors”), who shall initially be Xue Baizhong and Liu Qiang and two individuals to be
designated by the Management Holding Companies in due course; and 
 (b) one (1) member of the Company’s Board of
Directors designated by the holders of a majority of the outstanding Preference A Shares of the Company (the “Preference Director”), provided that for so long as Sequoia Capital China Growth Fund I, I.P. or its affiliates
(“Sequoia”) holds at least 5% the number of Preference A Shares originally purchased by Sequoia the Preference Director shall be designated by Sequoia, which designee shall initially be Neil Shen. 
 1.2 Appointment of Directors. In the event of the resignation, death, removal or disqualification of a director selected in
the manner set forth in Section 1.1 hereof, the party or parties holding the right to nominate such director shall promptly nominate a new director, and provide written notice of the nomination to the other parties to this Agreement, each of
whom shall promptly vote its shares of the Company to elect such nominee to the Board of Directors. 
 1.3 Removal.
Any party or parties to this Agreement having the right to nominate a director pursuant to Section 1.1 of this Agreement may remove its designated director at any time and from time to time, with or without cause (subject to the
Company’s Amended and Restated Memorandum and Articles of Association, as may be amended from time to time (the “Restated Articles”) and any requirements of law), in its or their sole discretion, and after written notice to
each of the other parties hereto of the new nominee to replace such director, and each party to this Agreement shall promptly vote its shares of capital stock of the Company to elect such nominee to the Board of Directors. 
  

 2 

 1.4 Alternate Preference Director. The Preference Director shall be entitled
to designate an alternate, anytime and from time to time, to serve at any meeting of the Board of Directors or of any committee thereto, and such alternate shall be permitted to attend all meetings of the Board of Directors or of any committee and
vote on the Preference Director’s behalf. 
 1.5 Observer Rights. The Company shall invite a representative
of each Investor to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give each such representative copies of all notices, minutes, consents, and other materials that it provides to its
directors at the same time and in the same manner; provided, however, that each such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided. 
 2. Drag Along Rights. 
 2.1 If prior to the closing of a Qualified IPO (as defined in the Restated Articles), holders of 85% of the aggregate number of the Company’s outstanding shares of capital stock (assuming conversion
of all Preference Shares of the Company into Ordinary Shares), voting together as a single class (collectively, the “Approving Members”), vote in favor of, otherwise consent in writing to, and/or otherwise agree in writing to sell
or transfer all of their shares in any Sale Transaction (as defined in the Restated Articles), then the Company shall promptly notify each of the remaining members of the Company, including the Management Holding Companies and the Management
Shareholder, if applicable (the “Remaining Members”) in writing of such vote, consent and/or agreement and the material terms and conditions of such Sale Transaction, whereupon each Remaining Member shall, in accordance with
instructions received from the Company, vote all of its voting securities of the Company in favor of, otherwise consent in writing to, and/or otherwise sell or transfer all of its shares in such Sale Transaction (including without limitation
tendering original share certificates for transfer, signing and delivering share transfer certificates, share sale or exchange agreements, and certificates of indemnity relating to any shares in the capital of the Company in the event that such
Remaining Member has lost or misplaced the relevant share certificate, in each case as applicable) on the same terms and conditions as were agreed to by the Approving Members and the Board of Directors; provided, however, that such
terms and conditions, including with respect to the price paid or received per share, may differ as between the Ordinary Shares and Preference A Shares and different series of Preference Shares, if any (including without limitation, in order to
reflect the Liquidation Preferences (as set forth in the Restated Articles) and participation rights of the Preference Shares as set forth in Restated Articles). 
 2.2 In furtherance of Section 2.1 above, the Company is hereby expressly authorized by each Remaining Member to take any and all of the following actions on such Remaining Member’s behalf
(without receipt of any further consent by such Remaining Member): (i) vote all of the voting securities of such Remaining Member in favor of any such Sale Transaction; (ii) otherwise consent on such Remaining Member’s behalf to such
Sale Transaction; (iii) sell all of such Remaining Member’s shares in such Sale Transaction, in accordance with the terms and conditions hereof; and (iv) act as the Remaining Member’s attorney-in-fact in relation to any such Sale
Transaction and have the full authority to sign and deliver, on behalf of such Remaining Member, share transfer certificates, share sale or exchange agreements and certificates of indemnity relating to any shares in the capital of the Company in the
event that such Remaining Member has lost or misplaced the relevant share certificate, in each case as applicable. 
  

 3 

 2.3 Notwithstanding Sections 2.1 and 2.2, the Remaining Members shall not be obligated to
vote, consent and/or sell their shares in connection with any such Sale Transaction to the extent that all of the Approving Members do not also do so with respect to all the Company’s shares held by them. 
 3. Additional Representations and Covenants. 
 3.1 No Revocation. The voting agreements contained herein are coupled with an interest and may not be revoked during the term of this Agreement. 
 3.2 Change in Number of Directors. The Investors, the Management Holding Companies and the Management Shareholder will not
vote for any amendment or change to the Company’s Restated Articles providing for the election of more or less than five (5) directors, or any other amendment or change to the Restated Articles inconsistent with the terms of this Agreement
unless otherwise approved by the holders of at least a majority of the Preference A Shares. 
 3.3 Legends. Each
certificate representing shares of the Company’s capital stock held by the Investors, the Management Shareholder or any of their respective successors and assignees shall bear the following legend: 
 “THE SHARES EVIDENCED HEREBY ARE SUBJECT TO A VOTING AGREEMENT BY AND AMONG THE COMPANY AND CERTAIN MEMBERS OF THE COMPANY (A COPY OF
WHICH MAY BE OBTAINED FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID VOTING AGREEMENT.” 
 3.4 Grant of Proxy. Upon the failure of any party to this Agreement to vote his/her/its shares of capital stock of the Company
in accordance with the terms of Sections 1 and 2 of this Agreement, such party hereby appoints and constitutes the Company as the attorney and proxy of such party with the full power of substitution and resubstitution, to the full extent of such
party’s rights, with respect to all voting capital stock of the Company owned by such shareholder, which proxy (the “Proxy”) shall be irrevocable until this Agreement terminates pursuant to its terms or this Section 3.4 of
this Agreement is amended to remove such party’s grant of proxy in accordance with Section 5.3 hereof, to vote all shares of capital stock then held by such party in the manner provided in Section 1 hereof. The parties agree that the
Proxy is coupled with an interest. 
  

 4 

 3.5 Specific Enforcement. It is agreed and understood that monetary damages
would not adequately compensate an injured party for the breach of this Agreement by any other party, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a
temporary or permanent injunction or restraining order. Further, each party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach 
 3.6 Indemnification; Reimbursement. The Company and each member of the Board of Directors elected pursuant to this Agreement
shall execute an indemnification agreement in the form attached to the Purchase Agreement. The Company shall also reimburse the Preference Director for all reasonable expenses incurred in his/her service as member of the Board of Directors.

 3.7 Overriding Obligations. None of the Investors, the Management Holding Companies and the Management
Shareholder shall have any obligation to act in accordance with any direction under Section 1 if he/she/it shall be required by any law or regulatory authority including but not limited to the United States Securities and Exchange Commission
not to so act, provided that if he/she/it could so act with the consent of or a waiver from any third party then he/she/it shall use his reasonable endeavors to obtain such consent or waiver and, having obtained the same, shall so act. 

4. Termination. 
 4.1 Termination Events. This Agreement shall terminate upon the earlier of: (a) the consummation of a Qualified IPO (as defined in the Restated Articles); or (b) the consummation
of a transaction or series of related transactions deemed to be a Liquidation Transaction (as such term is defined in the Restated Articles). 
 4.2 Removal of Legend. At any time after the termination of this Agreement in accordance with Section 4.1, any holder of a share certificate legended pursuant to Section 3.3 may
surrender such certificate to the Company for removal of the legend, and the Company will duly reissue a new certificate without the legend. 
 5. Miscellaneous. 
 5.1 Entire Agreement. This
Agreement constitutes the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing between the parties hereto are expressly
canceled. 
 5.2 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  

 5 

 5.3 Amendments and Waivers. Any term hereof may be amended or waived only with
the written agreement of the Company, the Management Holding Companies and holders of at least a majority of the Preference A Shares; provided, that any amendment or waiver that adversely affects any of the Investors shall require the consent
of such Investor. Notwithstanding the foregoing, this Agreement may be amended with only the written consent of the Company for the sole purpose of including additional purchasers of Preference A Shares pursuant to the Purchase Agreement as
“Investors.” Any amendment or waiver effected in accordance with this Section 5.3 shall be binding upon the Company, the Management Holding Companies, the Management Shareholder, any Investor, and each of their respective
successors and assigns. 
 5.4 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) upon confirmation of receipt, if sent by confirmed electronic mail or facsimile if sent during normal business
hours of the recipient, and if sent outside of normal business hours, then on the next Business Day, (c) upon receipt if sent utilizing an internationally recognized overnight courier, specifying next Business Day delivery, as evidenced by such
courier’s with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page or Exhibit A hereto, or to such e-mail address, facsimile number or address as
subsequently modified by written notice given in accordance with this Section 5.4. 
 5.5 Severability. If
one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement
for such provision, then (a) such provision shall be excluded from this Agreement, (b) the remainder of this Agreement shall be interpreted as if such provision were so excluded and (c) the remainder of this Agreement shall be
enforceable in accordance with its terms. 
 5.6 Governing Law. This Agreement and all acts and transactions
pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law. 
 5.7 Counterparts. This Agreement may be executed in two or more, counterparts, each of which shall be deemed an original and
all of which together shall constitute one instrument. 
 5.8 Titles and Subtitles. The titles and subtitles used
in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 5.9 No Liability for Election of Recommended Directors. Neither the Company, the Management Holding Companies, the Management Shareholder, the Investors, nor any officer, director, shareholder, partner, employee or agent of
any such party, makes any representation or warranty as to the fitness or competence of the nominee of any party hereunder to serve on the Company’s Board of Directors by virtue of such party’s execution of this Agreement or by the act of
such party in voting for such nominee pursuant to this Agreement. 
  

 6 

 5.10 Aggregation of Shares. All shares held or acquired by affiliated entities
(including affiliated venture funds) or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 5.11 Assignment of Rights. Notwithstanding anything to the contrary in this Agreement, the rights of the Investors in this Agreement may be assigned by an Investor, without any amendment of
this Agreement or any consent or approval of any party hereto, to a transferee or assignee that is an affiliated fund or entity of the Investor, which means with respect to a limited liability company or a limited liability partnership, a fund or
entity managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management company.

 5.12 Share Splits, Share Dividends, etc. In the event of any issuance of shares of the Company’s voting
securities hereafter to any of the parties hereto (including, without limitation, in connection with any Recapitalizations), such shares shall become subject to this Agreement and shall be endorsed with the legend set forth in Section 3.3.

 5.13 Supremacy of this Agreement. If and to the extent that there are inconsistencies between the provisions of
this Agreement and those of the Restated Articles, the terms of this Agreement shall prevail as between the parties hereto only, who hereby undertake to take all actions necessary or advisable, as promptly as practicable after the discovery of such
inconsistency, to amend the Restated Articles so as to eliminate such inconsistency to the largest extent as permitted by the applicable law. 
 5.14 Dispute Resolution. 
 (a) Negotiation Between Parties;
Mediations. The parties agree to negotiate in good faith to resolve any dispute between them regarding this Agreement. If the negotiations do not resolve the dispute to the reasonable satisfaction of both parties, then each party that is a
company shall nominate one authorized officer as its representative. The parties or their representatives, as the case may be, shall, within thirty (30) days of a written request by either party to call such a meeting, meet in person and shall
attempt in good faith to resolve the dispute. If the disputes cannot be resolved by such representatives in such meeting, the parties agree that they shall, if requested in writing by either party, meet within thirty (30) days after such
written notification for one day with an impartial mediator and consider dispute resolution alternatives other than formal arbitration. If an alternative method of dispute resolution is not agreed upon in the one day mediation, either party may
begin formal arbitration proceedings to be conducted in accordance with subsection (b) below. This procedure shall be a prerequisite before taking any additional action hereunder. 
  

 7 

 (b) Arbitration. In the event the parties are unable to settle a dispute
between them regarding this Agreement in accordance with subsection (a) above, such dispute shall be referred to and finally settled by arbitration at the Hong Kong International Arbitration Centre in accordance with the UNCITRAL Arbitration
Rules (“UNCITRAL Rules”) in effect, which rules are deemed to be incorporated by reference into this subsection (b), subject to the following: (i) the arbitration tribunal shall consist of three (3) arbitrators to be
appointed according to the UNCITRAL Rules, and at least one arbitrator is licensed to practice California law; and (ii) the language of the arbitration shall be English. The prevailing party shall be entitled to reasonable attorney’s fees,
costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
 [Signature Pages
Follow] 
  

 8 

 The parties hereto have executed this Voting Agreement as of the date first written above.

  

			
	THE COMPANY:
	
	CHINA NUOKANG BIO-PHARMACEUTICAL PTY
		
	By:	 	 /s/ Xue Baizhong

	Name:	 	Xue Baizhong
	Title:	 	Director
		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219, Qingnian Street
		 	Shenhe District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4254
	Email:	 	LNNK_CEO@lnnk.net

 The parties hereto have executed this Voting Agreement as of the date first written above.

  

			
	MANAGEMENT HOLDING COMPANIES:
	
	Anglo China Bio-Technology Investment Holdings Limited
		
	By:	 	 /s/ Xue Baizhong

	Name:	 	Xue Baizhong
	Title:	 	Director
		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219, Qingnian Street
		 	Shenhe District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4254
	Email:	 	LNNK_CEO@lnnk.net
	
	Britain Ukan Technology Investment Holdings (Group) Limited
		
	By:	 	 /s/ Xue Baizhong

	Name:	 	Xue Baizhong
	Title:	 	Director
		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219, Qingnian Street,
		 	Shenhe District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4254
	Email:	 	LNNK_CEO@lnnk.net

 The parties hereto have executed this Voting Agreement as of the date first written above.

  

			
	MANAGEMENT SHAREHOLDER:
	
	 /s/ Xue Baizhong

	Xue Baizhong

		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219 Qingnian Street
		 	Shenyang District, Shenyang
		 	PRC 110016
	Fax:	 	0086 24 2396 4253
	E-mail:	 	LNNK_CEO@lnnk.net

 The parties hereto have executed this Voting Agreement as of the date first written above.

  

			
	INVESTOR:
	
	Sequoia Capital China Growth Fund I, L.P.
		
	By:	 	 /s/ Jimmy Wong

		
	Name:	 	 Jimmy Wong

		 	(print)
	Title:	 	 Authorized signatory

		
	Address:	 	Suite 2215, Two Pacific Place
		 	88 Queensway, Hong Kong
		 	PRC
	Fax:	 	00852 2501 8989
	Email:	 	wong@sequoiacap.com

 The parties hereto have executed this Voting Agreement as of the date first written above.

  

			
	INVESTOR:
	
	HBM BioMed China Limited
		
	By:	 	 /s/ Joanchim Rudolf

	Name:	 	Dr. Joachim Rudolf
	Title:	 	Director
		
	Address:	 	Centennial Towers, 3rd Floor
		 	2454 West Bay Road
		 	Grand Cayman, Cayman Islands
	Fax:	 	001 345 946-8002
		 	001 345 946-8003
	Email:	 	arnold@hbmcayman.com

 EXHIBIT A 
 SCHEDULE OF MANAGEMENT SHAREHOLDER 
  

					
	 Name
	  	 Addresses and Fax No. for Notice

			
	Xue Baizhong

	  	Address:	  	 C/11F, Huaxin International Tower
 No. 219, Qingnian Street
 Shenhe District
 Shenyang, PRC 110016

		  	Fax:	  	0086 24 2396 4254
		  	Email:	  	LNNK_CEO@lnnk.net
	
	SCHEDULE OF INVESTORS
		
	 Name
	  	 Addresses and Fax No. for Notice

			
	Sequoia Capital China Growth Fund I, L.P.	  	Address:	  	 Suite 2215, Two Pacific Place
 88 Queensway, Hong Kong
 PRC

		  	Fax:	  	00852 2501 8989
		  	Email:	  	wong@sequoiacap.com
			
	HBM BioMed China Limited	  	Address:	  	 Centennial Towers, 3rd Floor
 2454
West Bay Road
 Grand Cayman, Cayman Islands

		  	Attn:	  	John Arnold
		  	Title:	  	Chairman
		  	Fax:	  	 001 345 946-8002
 001 345
946-8003

		  	Email:	  	arnold@hbmcayman.comRight of First Refusal and Co-Sale Agreement dated December 20, 2007

 Exhibit 10.9 
 CHINA NUOKANG BIO-PHARMACEUTICAL PTY  
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 
 This Right of First Refusal and Co-Sale Agreement (the
“Agreement”) is made and entered into as of December 20, 2007 by and among CHINA NUOKANG BIO-PHARMACEUTICAL PTY (formerly Brighter Sky Limited), a Cayman Islands exempted company (the “Company”), Anglo China
Bio-Technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited, each a company organized and existing under the laws of the British Virgin Islands (collectively, the “Management Holding
Companies”), the person set forth on Exhibit A hereto (the “Management Shareholder”) and the holders of Preference A Shares listed on Exhibit A hereto (collectively, the “Preference A
Holders” or “Investors”). 
 RECITALS 
 The Company, the Management Shareholder and the Investors have entered into a Preference A Shares Purchase Agreement dated as of the date
hereof (the “Purchase Agreement”), pursuant to which the Company desires to sell to the Investors and the Investors desire to purchase from the Company its Preference A Shares. A condition to the Investors’ obligations under
the Purchase Agreement is that the Company, the Management Holding Companies, the Management Shareholder and the Investors enter into this Agreement in order to provide the Company and the Investors the opportunity to purchase and/or participate,
upon the terms and conditions set forth in this Agreement, in subsequent sales by any Management Holding Company or the Management Shareholder of the capital shares of the Company or any Management Holding Company. The Company, the Management
Holding Companies, and the Management Shareholder desire to induce the Investors to purchase Preference A Shares pursuant to the Purchase Agreement by agreeing to the terms and conditions set forth below. 
 AGREEMENT 
 The parties agree as follows: 
 1. Sales by Restricted Sellers. 
 1.1 Right of First Refusal; Assignment of Company Right of First Refusal. 
 (a) Right of First Refusal. Should any Management Holding Company or the Management Shareholder (or a Permitted Transferee,
as defined below) (each, a “Restricted Seller” and collectively, the “Restricted Sellers”) propose to accept one or more bona fide offers (collectively, a “Purchase Offer”) from any persons to
purchase the Company’s Ordinary Shares or Preference A Shares and/or the capital shares of any of the Management Holding Companies (the “Shares”) from such Restricted Seller (other than as set forth in Section 1.5 of this
Agreement), such Restricted Seller shall promptly deliver a notice (the “Notice”) to the Company and each Investor stating the terms and conditions of such Purchase Offer including, without limitation, the number of Shares proposed
to be sold or transferred, the nature of such sale or transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. For purposes of this Section 1.1 only, “Shares” shall include any
capital shares of the Company or any Management Holding Company issued after the date hereof. The Company shall have the right to purchase all of the Shares proposed to be transferred at the price per share determined pursuant to Section 1.1(b)
below. The right to purchase such Shares shall be provided to the Company for a period of forth-five (45) days following receipt by the Company of written notice by the Restricted Seller. For purposes of this Section 1.1,
“Investors” shall include any general partners, managing members or affiliates of an Investor, including any “Affiliated Funds.” An “Affiliated Fund” shall mean an affiliated fund or entity of an Investor, which
means with respect to a limited liability company or a limited liability partnership, a fund or entity managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under
common control with such manager or managing member or general partner or management company. 
  

 1 

 (b) Price for Shares. With respect to any Shares to be transferred
pursuant to Section 1.1(a), the price per Share shall be a price set by the Board of Directors of the Company that will reflect the current value of the Shares in terms of present earnings and future prospects of the Company or the Management
Holding Company, as the case may be. The Company shall notify the Restricted Seller (or his or her executor, if involuntary transfer) of the price so determined within thirty (30) days after receipt by it of written notice of the transfer or
proposed transfer of Shares. However, if the Restricted Seller (or his or her executor) does not agree with the valuation as determined by the Board of Directors of the Company, the Restricted Seller (or his or her executor) shall be entitled to
have the valuation determined by an independent appraiser to be mutually agreed upon by the Company and the Restricted Seller (or his or her executor) and whose fees shall be borne equally by the Company and the Restricted Seller (or his or her
executor). 
 (c) Assignment of Right of First Refusal. The Company agrees that in the event that the
Company declines to exercise in full the right of first refusal set forth in Section 1.1(a) above (the “Right of First Refusal”), the Company will provide each Investor with notice of such determination at least fifteen
(15) days prior to the end of the period in which the Right of First Refusal expires under Section 1.1(a). Each Investor shall then have the right to submit, prior to the end of such period, notice of its irrevocable commitment to
exercise such Right of First Refusal within fifteen (15) days after receipt of the Company’s notice, as the Company’s assignee on a pro rata basis, based upon the number of Conversion Shares (as defined below) held by such Investor
relative to the aggregate number of Conversion Shares held by all Investors. Upon expiration or exercise of the Right of First Refusal, the Company will provide notice to the Restricted Sellers as to whether or not the Right of First Refusal has
been or will be exercised by the Company or the Investors. In the event that not all of the Investors elect to purchase all of their pro rata amount of the Shares, then the Company shall promptly give written notice to each of the Investors who have
fully exercised their Right of First Refusal under this Section 1.1(c) (the “Overallotment Notice”), which shall set forth the number of Shares of the Restricted Seller not purchased by the Company or the other Investors and
available for purchase, and shall offer such fully exercising Investors the right to acquire such unsubscribed shares. Each fully exercising Investor shall have five (5) days after receipt of the Overallotment Notice (the “Overallotment
Period”) to deliver a notice (the “Exercising Investors Notice”) to the Restricted Seller of its irrevocable commitment to purchase the shares available for purchase on a pro rata basis, based upon the number of Conversion
Shares held by such Investor relative to the aggregate number of Conversion Shares held by all fully exercising Investors. Such fully exercising Investors shall then effect the purchase of the Shares, including payment of the purchase price, not
more than five (5) days after delivery of the Exercising Investors Notice, and at such time, the Restricted Seller shall deliver to such fully exercising Investors the certificates representing the Shares to be purchased by such fully
exercising Investors, each certificate to be properly endorsed for transfer. 
  

 2 

 (d) Restrictions Binding on Transferees. All transferees of Shares or
any interest therein will receive and hold such Shares or interest subject to the provisions of this Agreement. Any sale or transfer of the Shares shall be void unless the provisions of this Agreement are satisfied. 
 1.2 Co-Sale Right. To the extent that the Right of First Refusal is not exercised by the Company or by the Investors, each
Investor electing not to exercise its Right of First Refusal shall have the right (the “Co-Sale Right”), exercisable upon written notice to the Company and the Restricted Seller within fifteen (15) business days after the
expiration of the Right of First Refusal or the Overallotment Period, if applicable, to participate in such sale of Shares by the Restricted Seller pursuant to the specified terms and conditions of such Purchase Offer. To the extent an Investor
exercises such Co-Sale Right in accordance with the terms and conditions set forth below, the number of Shares which such Restricted Seller may sell pursuant to such Purchase Offer shall be correspondingly reduced. The Co-Sale Right of each Investor
shall be subject to the following terms and conditions: 
 (a) Calculation of Shares. Each Investor may sell all
or any part of that number of Ordinary Shares of the Company issued or issuable upon conversion of Preference A Shares (including in such calculation Preference A Shares issued or issuable upon the conversion or exercise of securities of the Company
held by such Investor), or Ordinary Shares received in connection with any share dividend, share split or other reclassification thereof (the “Conversion Shares”) equal to the product obtained by multiplying (i) the aggregate
number of Shares covered by the Purchase Offer by (ii) a fraction, the numerator of which is the number of Conversion Shares at the time owned by such Investor and the denominator of which is the sum of (A) the total number of Conversion
Shares at the time owned by all Investors participating in such sale plus (B) the total number of Shares at the time owned by such Restricted Seller, including shares transferred by such Restricted Seller to Permitted Transferees (as defined
below) in accordance with this Agreement (unless in the case of transfer by the Management Shareholder of any capital shares of any Management Holding Company and any company having control of such Management Holding Company, in which case the
shares transferred by such Restricted Seller shall not be included in the calculation). 
 (b) Delivery of
Certificates. Each Investor may effect its participation in the sale by delivering to the Restricted Seller for transfer to the prospective purchaser one or more certificates, properly endorsed for transfer, which represent the Conversion
Shares which such Investor elects to sell. 
  

 3 

 1.3 Transfer. The share certificate or certificates which the Investor
delivers to the Restricted Seller pursuant to Section 1.2 shall be delivered by such Restricted Seller to the prospective purchaser in consummation of the sale pursuant to the terms and conditions specified in the Notice, and such Restricted
Seller shall promptly after its receipt of the full consideration for all the Shares to be sold from the prospective purchaser or purchasers remit to such Investor that portion of the sale proceeds to which such Investor is entitled by reason of its
participation in such sale. To the extent that any prospective purchaser or purchasers prohibit such assignment or otherwise refuse to purchase Conversion Shares from an Investor exercising its Co-Sale Right hereunder, the Restricted Seller(s) shall
not sell to such prospective purchaser or purchasers any Shares unless and until, simultaneously with such sale, the Restricted Seller(s) shall purchase such Conversion Shares from such Investor for the same consideration and on the same terms and
conditions as the proposed transfer described in the Notice (which terms and conditions shall be no less favorable than those governing the sale to the purchaser by the Restricted Seller(s)). 
 1.4 No Adverse Effect. The exercise or non-exercise of the rights of the Investors hereunder to participate in one or more
sales of Shares made by any Management Holding Company or the Management Shareholder shall not adversely affect their rights to participate in subsequent sales of Shares by the same or a different Management Holding Company or Management
Shareholder. 
 1.5 Permitted Transactions. The provisions of Section 1 of this Agreement shall not pertain
or apply to any transfer to the Management Shareholder’s ancestors, descendants or spouse or to a trust for his benefit or any other similar transfers in connection with estate planning. 
 1.6 Assignment of Rights. The rights of the Investors set forth in this Section 1 may be assigned (but only with all
related obligations) only to, without regard to the minimum number of an Investor’s Conversion Shares, a transferee or assignee of at least 10% of an Investor’s Conversion Shares set forth on Exhibit A (or all of such Investor’s
Conversion Shares if such Investor holds less than 10% of such amount) provided that (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the
securities with respect to which such rights are being assigned, and (b) such transferee agrees in writing to be bound by the provisions of this Agreement. Notwithstanding the foregoing, any Investor may transfer its rights set forth in this
Section 1 without regard to the minimum number of Conversion Shares described in the first sentence of this Section 1.6 if the transferee is a subsidiary, parent, partner, limited partner, retired partner, member, retired member or
shareholder of the Investor or an entity controlling, controlled by or under common control with such Investor, including any Affiliated Funds. 
 2. Sales by the Investors. 
 2.1 Right of First
Purchase. 
 (a) Right of First Purchase. If any Investor proposes to transfer (a) any Preference A
Shares, Ordinary Shares, or any shares in the capital of the Company or (b) any shares in a Management Holding Company (collectively, the “Sale Shares”), such Investor shall give a right of first purchase to the Company and
each Management Holding Company to purchase the Sale Shares on the same terms and conditions (including price) as such Investor proposes to transfer to a bona fide third party purchaser. The Investor shall first give a written notice to the Company
and each Management Holding Company (the “Sale Notice”) and the Sale Notice shall (i) enclose a copy of the offer that the Investor intends in good faith to submit to a third party or has received from a third party,
(ii) include, without limitation, the number of Sale Shares proposed to be sold or transferred, the nature of such sale or transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. Upon
receipt of such Sale Notice, the Company or any Management Holding Company, as the case may be, shall have fifteen (15) Business Days to notify such Investor whether or not it wishes to exercise such right of first purchase. If the Company or
any Management Holding Company declines to exercise such right of first purchase or fails to notify the Investor within the prescribed time or, if having exercised such right, fails to complete the sale within a further forty-five (45) Business
Days, the Investor shall be entitled to sell the Sale Shares to the third party purchaser on the same or no more favorable terms and conditions. For purposes of this Section 2.1, “Sale Shares” shall include any capital shares of the
Company or any Management Holding Company the Investors acquire after the date hereof. 
  

 4 

 (b) Restrictions on the Transfer of Sale Shares to a Third Party
Transferee. If the Company or any Management Holding Company, as the case may be, waives its priority right to purchase the Sale Shares, the Investor may transfer the Sale Shares to a third party and shall provide the Company or any
Management Holding Company with a copy of the executed written agreement between the Investor and the third party. The Investor agrees that as a condition precedent to any transfer of Sale Shares to a third party, the transferee must execute a
document of ratification and accession, specifying that the transferee shall be bound by and entitled to the obligations and rights and interests of this Agreement as if it were an original party to this Agreement. 
 3. Transfer Restrictions. 
 3.1 Prohibited Transfers. Any attempt by a Restricted Seller to transfer Shares in violation of Section 1 of this Agreement shall be void, and the Company and the Management Holding
Companies agree that neither shall effect such a transfer or treat any alleged transferee as the holder of such Shares without the written consent of the holders of at least a majority of the Conversion Shares. 
 3.2 Legended Certificates. Each certificate representing the Ordinary Shares and the Preference Shares of the Company
and each certificate representing ordinary shares of any Management Holding Company, now or hereafter owned by the Management Holding Companies or the Management Shareholder or issued to any Permitted Transferee pursuant to Section 1.5 shall
bear the following legend: 
 “THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS
CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND BETWEEN THE SHAREHOLDER, THE COMPANY AND CERTAIN HOLDERS OF ORDINARY AND PREFERENCE A SHARES OF THE COMPANY. COPIES OF SUCH AGREEMENT
MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.” 
  

 5 

 4. Termination. 
 4.1 Termination Events. This Agreement shall terminate upon the earliest to occur of any one of the following events (and
shall not apply to any transfer by a Restricted Seller in connection with any such event): 
 (a) The liquidation, dissolution
or indefinite cessation of the business operations of the Company, including but not limited to a Liquidation Transaction (as such term is defined in the Company’s Amended and Restated Memorandum and Articles of Association (the
“Restated Articles”)); 
 (b) The execution by the Company of a general assignment for the benefit of
creditors or the appointment of a receiver or trustee to take possession of the property and assets of the Company; 
 (c) A
Qualified IPO (as defined in the Restated Articles); or 
 (d) A Sale Transaction (as defined in the Restated Articles).

 4.2 Removal of Legend. At any time after the termination of this Agreement in accordance with Section 4.1,
any holder of a share certificate legended pursuant to Section 3.2 may surrender such certificate to the Company for removal of such legend, and the Company will duly reissue a new certificate without the legend. 
 5. Miscellaneous. 
 5.1 Successors and Assigns. Except as otherwise provided herein, this Agreement and the rights and obligations of the parties hereunder shall inure to the benefit of, and be binding upon,
the parties’ respective successors, assigns and legal representatives. 
 5.2 Amendments and Waivers. Any
term of this Agreement may be amended or waived only with the written consent of the Company, the Management Holding Companies, and holders of at least a majority of the Preference A Shares; provided, that any amendment or waiver that
adversely affects any of the Investors shall require the consent of such Investor. Notwithstanding the foregoing, this Agreement may be amended with only the written consent of the Company for the sole purpose of including additional purchasers of
Preference A Shares pursuant to the Purchase Agreement as “Investors.” Any amendment or waiver effected in accordance with this Section 6.3 shall be binding upon the Company, the Management Holding Companies, the Management
Shareholder, any Investor, and each of their respective successors and assigns. 
 5.3 Notices. All notices and
other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) upon confirmation of receipt, if sent by confirmed
electronic mail or facsimile if sent during normal business hours of the recipient, and if sent outside of normal business hours, then on the next Business Day, (c) upon receipt if sent utilizing an internationally recognized overnight courier,
specifying next Business Day delivery, as evidenced by such courier’s with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page or Exhibit A
hereto, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section 5.3. 
  

 6 

 5.4 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be
excluded from this Agreement, (b) the remainder of this Agreement shall be interpreted as if such provision were so excluded and (c) the remainder of this Agreement shall be enforceable in accordance with its terms. 
 5.5 Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties
hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law. 
 5.6 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same
instrument. 
 5.7 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience
only and are not to be considered in construing or interpreting this Agreement. 
 5.8 Aggregation of Shares. All
shares held or acquired by affiliated entities (including Affiliated Funds) or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 5.9 Effect of Change in Company’s Capital Structure. If, from time to time, the Company pays a share dividend or effects
a share split or other change in the character or amount of any of the outstanding stock of the Company, then in such event any and all new, substituted or additional securities to which any Management Holding Company or any Management Shareholder
is entitled by reason of the Management Holding Company’s or the Management Shareholder’s ownership of the capital shares of the Company shall immediately be subject to the rights and obligations set forth in this Agreement with the same
force and effect as the stock subject to such rights immediately before such event. 
 5.10 Dispute Resolution. 

 (a) Negotiation Between Parties; Mediations. The parties agree to negotiate in good faith to resolve any
dispute between them regarding this Agreement. If the negotiations do not resolve the dispute to the reasonable satisfaction of both parties, then each party that is a company shall nominate one authorized officer as its representative. The parties
or their representatives, as the case may be, shall, within thirty (30) days of a written request by either party to call such a meeting, meet in person and shall attempt in good faith to resolve the dispute. If the disputes cannot be resolved
by such representatives in such meeting, the parties agree that they shall, if requested in writing by either party, meet within thirty (30) days after such written notification for one day with an impartial mediator and consider dispute
resolution alternatives other than formal arbitration. If an alternative method of dispute resolution is not agreed upon in the one day mediation, either party may begin formal arbitration proceedings to be conducted in accordance with subsection
(b) below. This procedure shall be a prerequisite before taking any additional action hereunder. 
  

 7 

 (b) Arbitration. In the event the parties are unable to settle a dispute
between them regarding this Agreement in accordance with subsection (a) above, such dispute shall be referred to and finally settled by arbitration at the Hong Kong International Arbitration Centre in accordance with the UNCITRAL Arbitration
Rules (“UNCITRAL Rules”) in effect, which rules are deemed to be incorporated by reference into this subsection (b), subject to the following: (i) the arbitration tribunal shall consist of three (3) arbitrators to be
appointed according to the UNCITRAL Rules, and at least one arbitrator is licensed to practice California law; and (ii) the language of the arbitration shall be English. The prevailing party shall be entitled to reasonable attorney’s fees,
costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
 [Signature Pages
Follow] 
  

 8 

 The parties have executed this Right of First Refusal and Co-Sale Agreement as of the date
first written above. 
  

			
	THE COMPANY:
	
	CHINA NUOKANG BIO-PHARMACEUTICAL PTY
		
	By:	 	 /s/ Xue Baizhong

	Name:	 	Xue Baizhong
	Title:	 	Director
		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219, Qingnian Street
		 	Shenhe District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4254
	Email:	 	LNNK_CEO@lnnk.net

 The parties have executed this Right of First Refusal and Co-Sale Agreement as of the date
first written above. 
  

			
	MANAGEMENT HOLDING COMPANIES:
	
	 Anglo China Bio-Technology Investment
 Holdings Limited

		
	By:	 	 /s/ Xue Baizhong

	Name:	 	Xue Baizhong
	Title:	 	Director
		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219, Qingnian Street
		 	Shenhe District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4254
	Email:	 	LNNK_CEO@lnnk.net
	
	 Britain Ukan Technology Investment
 Holdings (Group) Limited

		
	By:	 	 /s/ Xue Baizhong

	Name:	 	Xue Baizhong
	Title:	 	Director
		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219, Qingnian Street
		 	Shenhe District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4254
	Email:	 	LNNK_CEO@lnnk.net

 The parties have executed this Right of First Refusal and Co-Sale Agreement as of the date
first written above. 
  

			
	MANAGEMENT SHAREHOLDER:
	
	 /s/ Xue Baizhong

	Xue Baizhong

		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219 Qingnian Street
		 	Shenyang District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4253
	E-mail:	 	Address: LNNK_CEO@lnnk.net

 The parties have executed this Right of First Refusal and Co-Sale Agreement as of the date
first written above. 
  

			
	INVESTOR:
	
	Sequoia Capital China Growth Fund I, L.P.
		
	By:	 	 /s/ Jimmy Wong

		
	Name:	 	 /s/ Jimmy Wong

		 	(print)
	Title:	 	 /s/ Authorized signatory

		
	Address:	 	Suite 2215, Two Pacific Place
		 	88 Queensway, Hong Kong
		 	PRC
	Fax:	 	00852 2501 8989
	Email:	 	wong@sequoiacap.com

 The parties have executed this Right of First Refusal and Co-Sale Agreement as of the date
first written above. 
  

			
	INVESTOR:
	
	HBM BioMed China Limited
		
	By:	 	 /s/ Jaochim Rudolf

	Name:	 	Dr. Joachim Rudolf
	Title:	 	Director
		
	Address:	 	Centennial Towers, 3rd Floor
		 	2454 West Bay Road
		 	Grand Cayman, Cayman Islands
	Fax:	 	001 345 946-8002
		 	001 345 946-8003
	Email:	 	arnold@hbmcayman.com

 EXHIBIT A 
 SCHEDULE OF MANAGEMENT SHAREHOLDER 
  

							
	 Name
	  	 Addresses and Fax No. for Notice
	  	 
			
	Xue Baizhong

	  	Address:	  	 C/11F, Huaxin International Tower
 No. 219, Qingnian Street
 Shenhe District
 Shenyang, PRC 110016

		  	Fax:	  	0086 24 2396 4254	  	
		  	Email:	  	LNNK_CEO@lnnk.net	  	

 SCHEDULE OF INVESTORS 
  

							
	 Name
	  	 Addresses and Fax No. for Notice
	  	 
			
	Sequoia Capital China Growth Fund I, L.P.	  	Address:	  	 Suite 2215, Two Pacific Place
 88 Queensway, Hong Kong
 PRC

		  	Fax:	  	00852 2501 8989	  	
		  	Email:	  	wong@sequoiacap.com	  	
			
	HBM BioMed China Limited	  	Address:	  	 Centennial Towers, 3rd Floor
 2454
West Bay Road
 Grand Cayman, Cayman Islands

		  	Attn:	  	John Arnold	  	
		  	Title:	  	Chairman	  	
		  	Fax:	  	 001 345 946-8002
 001 345
946-8003
	  	
		  	Email:	  	arnold@hbmcayman.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]